Diagnosis of Diabetes and Prediabetes

Normal, prediabetes and diabetes on the ADA, WHO and Indian criteria, and why a value at target is not a normal value · v1.1

  • Say first whether the person already has diabetes, because the same number is read against a diagnostic threshold in one case and against a treatment target in the other.
  • Enter whichever results exist: fasting, 2-hour, random, HbA1c. One is enough to start; two are needed to confirm.
  • Tick anything that makes the HbA1c unreliable. The tool then reads the glucose values alone and says so.
  • The tool gives back one verdict, normal, prediabetes or diabetes, with the criteria that produced it, and a band graphic for each test showing where the value sits and where the treatment target would sit.
  • Read the graphic as the point of the tool: the blue target bracket reaches into the amber and red bands, which is why a result at target is not a normal result.

  • The type of diabetes. This tool decides whether diabetes is present. Type 1, type 2, LADA, monogenic and pancreatic diabetes are separated by the Diabetes Classification pathway.
  • Children under 18, in whom the same thresholds apply but the screening rules and the differential do not.
  • Treatment: the choice of drug, the individualised HbA1c target with its rationale, and insulin dosing. Those belong to the outpatient management, inpatient insulin and ketoacidosis modules linked from the result.
  • A diagnosis from a capillary glucometer reading or from continuous glucose monitoring. Every threshold here is a venous plasma value from a laboratory, and the ADA states that CGM has insufficient evidence for diagnosis.
  • The two-step 50 g and 100 g pregnancy test. It is printed in the Criteria tab for reference and is not used in India.

1. The Question Being Asked

This is the field that changes what every number below means. A fasting glucose of 120 mg/dL is impaired fasting glucose in the first case and inside the treatment target in the second.
Pregnancy has its own thresholds, its own national test and its own targets. The non-pregnant categories of impaired fasting glucose and impaired glucose tolerance do not apply.

2. The Results enter whichever exist; venous plasma, laboratory measured

Applies to every glucose field below. The thresholds are compared in the unit entered, so 7.0 mmol/L and 126 mg/dL read identically.
Fasting is no caloric intake for at least 8 hours.
75 g anhydrous glucose in water after an overnight fast, with at least 150 g of carbohydrate a day for the 3 days before.
Optional. Read against the International Diabetes Federation 2024 position, which no Indian guideline and neither the ADA nor WHO has adopted. It is printed as an advisory and never decides the verdict.
Any time of day, without regard to the last meal. Diagnostic only at 200 mg/dL or more with symptoms.
From an NGSP-certified, DCCT-aligned laboratory method. A point-of-care device is acceptable for diagnosis only if it is certified for diagnosis and run in a certified laboratory.
Every number this tool uses, and the document it came from. Two kinds of number appear on this page and they must not be confused. A diagnostic threshold separates people who have diabetes from people who do not. A treatment target is the level a person who already has diabetes is asked to reach. The second is deliberately set inside the range that the first would call abnormal.

1. Diagnostic Thresholds, Non-Pregnant Adults

TestNormalIntermediateDiabetesSource
Fasting plasma glucose<100 mg/dL (5.6 mmol/L) on the ADA range; <110 mg/dL (6.1) on the WHO and RSSDI rangeImpaired fasting glucose: 100 to 125 mg/dL (ADA); 110 to 125 mg/dL (WHO 1999 and 2006, RSSDI 2022). ICMR 2018 prints both and adjudicates neither≥126 mg/dL (7.0 mmol/L)ADA 2026, WHO 2006, ICMR 2018, RSSDI 2022
2-hour plasma glucose, 75 g OGTT<140 mg/dL (7.8 mmol/L)Impaired glucose tolerance: 140 to 199 mg/dL (7.8 to 11.0 mmol/L)≥200 mg/dL (11.1 mmol/L)All four agree
HbA1c<5.7 per cent (39 mmol/mol) on the ADA range. WHO defines no intermediate range5.7 to 6.4 per cent (39 to 47 mmol/mol), ADA and RSSDI≥6.5 per cent (48 mmol/mol), NGSP-certified assayInternational Expert Committee 2009, ADA 2010 onward, WHO 2011, ICMR 2018, RSSDI 2022
Random plasma glucoseNot a screening thresholdNot defined. A value of 140 to 199 mg/dL calls for a fasting test or an HbA1c≥200 mg/dL (11.1 mmol/L) with classic symptoms or a hyperglycaemic crisisADA 2026, ICMR 2018
1-hour plasma glucose, 75 g OGTT<155 mg/dL (8.6 mmol/L)≥155 mg/dL: intermediate hyperglycaemia≥209 mg/dL (11.6 mmol/L), to be confirmed by repeatIDF position statement 2024 only. Not adopted by ADA 2026, WHO, ICMR or RSSDI
The confirmation rule. Without unequivocal hyperglycaemia, the ADA requires two abnormal results: two different tests from the same sample, or the same test at two time points. If two different tests disagree, the one above the threshold is repeated, and the diagnosis rests on the repeated test. A result close to the threshold is repeated in 3 to 6 months. WHO 1999 puts it more plainly: the diagnosis in an asymptomatic person is never made on a single value.

2. Thresholds in Pregnancy

TestGestational diabetesNotesSource
DIPSI: 75 g glucose, irrespective of the last meal, 2-hour plasma glucose≥140 mg/dL (7.8 mmol/L)120 to 139 mg/dL is gestational glucose intolerance and is followed up. The national test at the first contact and at 24 to 28 weeks. Against IADPSG its sensitivity was 22.6 per cent in 1,031 womenMoHFW 2018, DIPSI
IADPSG one-step: fasting 75 g OGTTFasting ≥92 mg/dL (5.1), 1-hour ≥180 (10.0), 2-hour ≥153 (8.5). One value diagnosesDerived from HAPO at 1.75 times the odds of an adverse outcome. Raises the diagnosed prevalence roughly one- to threefoldIADPSG 2010, WHO 2013, ADA 2026
Two-step: 50 g screen then 100 g OGTTScreen positive at 130, 135 or 140 mg/dL at 1 hour; then two of fasting 95, 1-hour 180, 2-hour 155, 3-hour 140 (Carpenter-Coustan)The United States alternative. Not used in India; printed for reference onlyADA 2026 Table 2.8
Overt diabetes in pregnancyThe non-pregnant criteria: fasting ≥126, 2-hour ≥200, random ≥200 with symptoms, and HbA1c ≥6.5 per cent before 15 weeks (ADA 2.31a). From 15 weeks the HbA1c is set aside and plasma glucose decides (ADA 2.4)Classified as diabetes complicating pregnancy, not GDM, whenever it is found. Reclassify every GDM at 4 to 12 weeks post partum (ADA), 6 weeks under the national programme, using the non-pregnant criteriaADA 2026, MoHFW 2018

3. Treatment Targets, Which Are Not Normal Values

PopulationHbA1cFasting or pre-mealAfter mealsSource
Many non-pregnant adults with diabetes<7.0 per cent (53 mmol/mol); <6.5 may be appropriate where it can be reached without hypoglycaemia80 to 130 mg/dL (4.4 to 7.2 mmol/L)<180 mg/dL (10.0 mmol/L) at the peak, 1 to 2 hours after the start of the mealADA 2026, section 6
Continuous glucose monitoringTime in range 70 to 180 mg/dL above 70 per cent; below 70 mg/dL under 4 per cent; below 54 under 1 per centA time in range of 70 per cent corresponds to an HbA1c near 7 per centADA 2026, section 6
ICMR 2018Ideal <7 per cent; satisfactory 7 to under 8Ideal 80 to 110 mg/dL; satisfactory 111 to 1252-hour ideal 120 to 140 mg/dL; satisfactory 141 to 180ICMR 2018, section 4.1
RSSDI 2022<7.0 per cent160 mg/dL, as long as hypoglycaemia is avoidedRSSDI 2022
Older adult, generally healthy<7.0 to 7.5 per cent80 to 130 mg/dLBedtime 80 to 180 mg/dLADA 2026, section 13
Older adult, complex or intermediate health<8.0 per cent (64 mmol/mol)90 to 150 mg/dLBedtime 100 to 180 mg/dLADA 2026, section 13
Older adult, very complex or poor healthDo not rely on HbA1c; avoid hypoglycaemia and symptomatic hyperglycaemia100 to 180 mg/dLBedtime 110 to 200 mg/dLADA 2026, section 13
Pregnancy, any diabetes<6 per cent (42 mmol/mol) if achievable without hypoglycaemia; relaxed to <7 if necessary<95 mg/dL (5.3 mmol/L)1-hour <140 mg/dL or 2-hour <120 mg/dLADA 2026, section 15
Remission. The 2021 consensus convened by the ADA defines remission of type 2 diabetes as an HbA1c below 6.5 per cent measured at least 3 months after all glucose-lowering drugs have been stopped. It is not a return to normal glucose tolerance, it is not the removal of the diagnosis, and the complication surveillance continues. An HbA1c in the non-diabetic range while a drug is being taken is a result at target, not remission.

4. When the HbA1c Cannot Be Used

ConditionDirection of errorWhat to do
Iron deficiency anaemia, B12 or folate deficiencyReduced red cell turnover: HbA1c reads falsely highDiagnose on plasma glucose. In India the NFHS-5 anaemia prevalence of 57 per cent among women makes this the commonest reason
Haemolysis, blood loss, transfusion, erythropoietin, pregnancy from 15 weeksIncreased turnover or dilution: HbA1c reads falsely lowDiagnose on plasma glucose. Before 15 weeks the ADA applies the standard criteria, HbA1c included; from 15 weeks use the pregnancy thresholds
Haemoglobin variant or trait: HbS, HbC, HbE, HbD, thalassaemiaAssay dependent, either directionUse an assay without interference for that variant (ngsp.org/interf.asp), or diagnose on glucose. RSSDI: fructosamine as a surrogate
Chronic kidney disease stage 4 or 5, dialysisFalsely low, from shortened red cell survival and erythropoietinDiagnose on glucose
HIV on antiretroviral treatment; G6PD deficiencyFalsely lowDiagnose on glucose (ADA 2026 recommendation 2.4)
Point-of-care deviceImprecisionAcceptable for diagnosis only when the device is certified for diagnosis and run in a certified laboratory

5. How the Thresholds Came to Sit Where They Do

YearDocumentWhat moved
1979National Diabetes Data GroupFasting 140 mg/dL, 2-hour 200 mg/dL, impaired glucose tolerance defined
1980 and 1985WHO Expert Committee and Study GroupAdopted the same frame internationally
1997ADA Expert CommitteeFasting lowered to 126 mg/dL, chosen because that is where the prevalence of retinopathy rises and where it matches the 2-hour 200; impaired fasting glucose introduced at 110 to 125
1999WHOAdopted 126 and 110 to 125; a single value never diagnoses an asymptomatic person
2003ADA follow-up reportImpaired fasting glucose lowered to 100. WHO did not follow, in 2006 or since
2009 and 2010International Expert Committee; ADAHbA1c 6.5 per cent for diagnosis; the ADA added 5.7 to 6.4
2011WHO; DETECT-2WHO accepted 6.5 with stringent quality assurance and no intermediate range. DETECT-2 pooled 44,623 people and found the retinopathy threshold at a fasting glucose of 6.5 mmol/L and an HbA1c of 6.5 per cent
2024International Diabetes FederationProposed the 1-hour value, 155 and 209 mg/dL. Not adopted by ADA 2026 or by any Indian document

1. The Difference Between a Normal Value and a Target

A diagnostic threshold is set where the risk of retinopathy begins to rise in a population without diabetes. A treatment target is set where the risk of hypoglycaemia and treatment burden begins to outweigh the benefit of lower glucose in a person who already has the disease. They answer different questions and were never intended to coincide.

  • An HbA1c of 6.2 per cent is prediabetes-range in a person without diabetes and at target in a person with it.
  • A fasting glucose of 120 mg/dL is impaired fasting glucose and is also inside the 80 to 130 target.
  • A fasting glucose of 93 mg/dL in pregnancy is gestational diabetes on IADPSG and is inside the treatment target of below 95.
  • A person with diabetes whose values fall into the non-diabetic range on treatment has reached target. The diagnosis stands, and remission is a separate, defined state.

2. The Two Definitions of Impaired Fasting Glucose

The ADA lowered the floor from 110 to 100 mg/dL in 2003 to make the fasting category as sensitive as impaired glucose tolerance. WHO kept 110 in 2006 because the lower floor more than doubles the number of people labelled, without evidence that the added group benefits from intervention. RSSDI 2022 follows WHO; ICMR 2018 prints both.

A fasting glucose of 105 mg/dL is prediabetes in a clinic that follows the ADA and normal in one that follows RSSDI. Neither is wrong. The tool reports both and asserts neither, and the record should name the range used.

3. What the Indian Prevalence Figures Mean at the Bedside

  • ICMR-INDIAB 2023, 113,043 adults across every state: diabetes 11.4 per cent, prediabetes 15.3 per cent, both by WHO criteria. In many states with a lower human development index there is more prediabetes than diabetes.
  • CURES 10-year follow-up, Chennai: 58.9 per cent of people with prediabetes converted to diabetes, and 19.4 per cent of those with normal glucose tolerance converted directly to diabetes within a decade. Among the highest conversion rates recorded anywhere.
  • IDPP-1, 531 Indian adults with impaired glucose tolerance: 55 per cent of the control group had diabetes within 3 years. Lifestyle advice reduced that by 28.5 per cent and metformin by 26.4 per cent; combining them added nothing. Number needed to treat 6.4.
  • The ADA screens from age 35, or at a body mass index of 23 with a risk factor in people of Asian ancestry. ICMR 2018 screens everyone above 30.

4. The Three Tests Do Not Find the Same People

In the CURES cohort, the prevalence of diabetes in 2,188 adults was 6.1 per cent by fasting glucose, 10.1 per cent by the 2-hour value and 12.8 per cent by HbA1c. Only 121 of the 281 diagnosed met all three criteria. The ADA records that the 2-hour value diagnoses more people than either of the others, and that the trials preventing progression were done in people with impaired glucose tolerance, not in isolated impaired fasting glucose or HbA1c-defined prediabetes.

  • The same Chennai laboratory found HbA1c cut points of 6.1 per cent against the 2-hour criterion and 6.4 against the fasting one, and 5.6 for the intermediate group at under 70 per cent accuracy. These are printed as context. The tool applies the international 6.5 and 5.7, as ICMR and RSSDI do.
  • A fasting glucose alone misses roughly a third of Indian diabetes. Where the fasting value is in the impaired range, the 2-hour test is the one that changes management.

5. Why HbA1c Fails More Often in India

HbA1c is a weighted average over the life of the red cell, so anything that shortens or lengthens that life moves the number without any change in glucose.

  • Iron deficiency raises it. NFHS-5 found anaemia in 57 per cent of women aged 15 to 49.
  • Haemoglobin variants are carried by 3 to 4 per cent of the population, more in the north-east for HbE and in the tribal belts for HbS, and interfere in an assay-dependent direction.
  • Pregnancy from the second trimester, transfusion, haemolysis, dialysis, erythropoietin and HIV treatment lower it. Before 15 weeks the ADA still applies the standard criteria, and an HbA1c of 5.9 to 6.4 per cent there marks early abnormal glucose metabolism (ADA 2.31b), a risk category rather than a diagnosis.
  • The ADA recommendation is plasma glucose in all of these. A haemoglobin variant is often first suspected from an HbA1c that does not fit the glucose, which is why the ADA asks for evaluation whenever the two disagree consistently.

6. The Confirmation Rule in Practice

Worked example. A 46-year-old man with no symptoms has a fasting glucose of 131 mg/dL and an HbA1c of 6.1 per cent from the same sample. The fasting value is in the diabetes range; the HbA1c is not. The tests disagree, so the fasting glucose is repeated on another day. If the repeat is 126 or more, he has diabetes, whatever the HbA1c says. If it is 119, he has impaired fasting glucose and is retested in 3 to 6 months. Neither test outranks the other; the repeated one decides.

Two abnormal results from different tests on the same sample also confirm. A fasting glucose of 140 and an HbA1c of 6.8 per cent from one venepuncture is a diagnosis, and the patient does not need to return fasting.

7. Diagnosis in Pregnancy and the National Test

  • DIPSI is the national test because it needs no fasting and one visit. Its threshold of 140 mg/dL was retained by the 2018 national guideline, with 120 to 139 followed up as gestational glucose intolerance.
  • Against IADPSG it is insensitive: 22.6 per cent in 1,031 women in one Chennai series. A negative DIPSI in a woman with risk factors does not settle the question, and a fasting 75 g test with IADPSG thresholds is the better test where it is feasible.
  • Every woman with gestational diabetes is reclassified after delivery with the non-pregnant criteria. The programme says 6 weeks; the ADA says 4 to 12 weeks, then every 1 to 3 years for life. The Pregnancy Timeline carries the schedule.

8. What Follows a New Diagnosis

The diagnosis is the beginning of a workup, not the end of one. The tool links to each step on the branch where it is wanted:

Abbreviations ACOG (American College of Obstetricians and Gynecologists) · ADA (American Diabetes Association) · B12 (Vitamin B12) · BMI (Body Mass Index) · CGM (Continuous Glucose Monitoring) · CURES (Chennai Urban Rural Epidemiology Study) · CVD (Cardiovascular Disease) · DCCT (Diabetes Control and Complications Trial) · DIPSI (Diabetes in Pregnancy Study Group India) · DKA (Diabetic Ketoacidosis) · FIB-4 (Fibrosis-4 Index) · G6PD (Glucose-6-Phosphate Dehydrogenase) · GDM (Gestational Diabetes Mellitus) · HAPO (Hyperglycemia and Adverse Pregnancy Outcome Study) · HbA1c (Glycated Haemoglobin) · HbC (Haemoglobin C) · HbD (Haemoglobin D) · HbE (Haemoglobin E) · HbS (Haemoglobin S) · HHS (Hyperglycaemic Hyperosmolar State) · HIV (Human Immunodeficiency Virus) · IADPSG (International Association of Diabetes and Pregnancy Study Groups) · ICMR (Indian Council of Medical Research) · ICMR-INDIAB (Indian Council of Medical Research India Diabetes Study) · IDF (International Diabetes Federation) · IDPP (Indian Diabetes Prevention Programme) · IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) · IFG (Impaired Fasting Glucose) · IGT (Impaired Glucose Tolerance) · LADA (Latent Autoimmune Diabetes in Adults) · MoHFW (Ministry of Health and Family Welfare) · NDDG (National Diabetes Data Group) · NFHS (National Family Health Survey) · NGSP (National Glycohemoglobin Standardization Program) · OGTT (Oral Glucose Tolerance Test) · RSSDI (Research Society for the Study of Diabetes in India) · UACR (Urine Albumin to Creatinine Ratio) · WHO (World Health Organization)
References
  1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S27-S49.
  2. American Diabetes Association Professional Practice Committee. 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149.
  3. American Diabetes Association Professional Practice Committee. 13. Older adults: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S277-S296.
  4. American Diabetes Association Professional Practice Committee. 15. Management of diabetes in pregnancy: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S321-S338.
  5. World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: WHO; 2006.
  6. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva: WHO; 2011. WHO/NMH/CHP/CPM/11.1.
  7. Indian Council of Medical Research. ICMR guidelines for management of type 2 diabetes 2018. New Delhi: ICMR; 2018.
  8. Research Society for the Study of Diabetes in India. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries 2022;42(Suppl 1):1-143.
  9. Maternal Health Division, Ministry of Health and Family Welfare, Government of India. Diagnosis and management of gestational diabetes mellitus: technical and operational guidelines for the implementation of maternal health programme. New Delhi: MoHFW; 2018.
  10. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33(3):676-82.
  11. Bergman M, Manco M, Satman I, et al. International Diabetes Federation position statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res Clin Pract 2024;209:111589.
  12. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 2021;44(10):2438-44.
  13. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28(12):1039-57.
  14. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20(7):1183-97.
  15. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11):3160-7.
  16. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32(7):1327-34.
  17. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K; DETECT-2 Collaboration Writing Group. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011;34(1):145-50.
  18. Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol 2023;11(7):474-89.
  19. Anjana RM, Shanthi Rani CS, Deepa M, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES). Diabetes Care 2015;38(8):1441-8.
  20. Mohan V, Vijayachandrika V, Gokulakrishnan K, et al. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care 2010;33(3):515-9, read with Nazir A, Papita R, Anbalagan VP, Anjana RM, Deepa M, Mohan V. Prevalence of diabetes in Asian Indians based on glycated hemoglobin and fasting and 2-h post-load (75-g) plasma glucose (CURES-120). Diabetes Technol Ther 2012;14(8):665-8.
  21. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49(2):289-97.
How to Cite This Tool

AMA Style:Umakanth S. Diagnosis of Diabetes and Prediabetes. Version 1.1. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/diabetes-diagnosis

Vancouver Style:Umakanth S. Diagnosis of Diabetes and Prediabetes [Internet]. Version 1.1. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/diabetes-diagnosis

Disclaimer and scope
Disclaimer: This decision-support system is written for healthcare professionals. It does not substitute clinical judgment, and the treating physician retains absolute responsibility for every diagnostic, dosing and therapeutic decision. The algorithms are built on the evidence as it stands, and the evidence moves. Verify the output against your current institutional protocol, and against the patient in front of you.
© 2026 MEDiscuss.org. All rights reserved. Provided free of charge for clinical use. Unauthorised reproduction or redistribution is strictly prohibited.
Category Risk Scores & Diagnostic PathwaysClassification
Specialties Endocrinology, Internal Medicine, Family Medicine, Community Medicine, Obstetrics and Gynaecology

Written and maintained by

Dr Shashikiran Umakanth

Last revised 6 September 2026

How these tools are written and reviewed

Related Clinical Tools
Diabetes Classification PathwayHbA1c TargetOutpatient Diabetes PathwayPregnancy & Antenatal Scheduler